Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Mayo Clinic
Summary
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Eligibility
- Age range
- 21–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Over the age of 21 * Must have an informant who will be able to provide independent evaluation of functioning * English is primary language * All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). * All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language * All subjects with typical amnestic AD must have relative preservation of episodic me…
Interventions
- DrugF-18 AV 1451
Tau binding agent
- DrugC-11 PiB
Amyloid binding agent
Location
- Mayo ClinicRochester, Minnesota